Therini Bio: $39 Million Series A Secured For Advancing Clinical Development Of Neurodegenerative Disease Immunotherapies
By Amit Chowdhry ● May 17, 2025
Therini Bio - a clinical-stage biotech company developing fibrin-targeting immunotherapies for neurodegenerative diseases driven by vascular dysfunction - announced that it raised $39 million in a Series A extension financing. This extension financing included new investors, Angelini Ventures and Apollo Health Ventures, along with existing investors SV Health Investors’ Biotech Fund and Dementia Discovery Fund, MRL Ventures Fund, Sanofi Ventures, Eli Lilly and Company, Dolby Family Ventures, and Foundation for a Better World. This financing funding Therini Bio’s Series A, bringing the total to $75 million.